SelectImmune Pharma

SelectImmune Pharma is a clinical-stage Swedish biotechnology company specializing in the development of immunotherapies for infectious diseases, particularly urinary tract infections (UTIs). The company's approach focuses on modulating the host's innate immune response to treat infections and prevent tissue damage, offering an alternative or supplement to traditional antibiotics. Their lead programs include the use of N-acetylcysteine to treat UTIs and the IL-1 receptor antagonist Kineret for bladder pain syndrome. Founded on research from Lund University, SelectImmune aims to address the global challenge of antibiotic resistance through innovative molecular targets. The company leverages proprietary insights into the genetic and molecular mechanisms of the immune system to identify new therapeutic candidates. SelectImmune is publicly traded on the Spotlight Stock Market in Sweden.